Abstract
Vascular complications result in disabilities and short life expectancy in diabetic patients. During prolonged hyperglycemic exposure, non-enzymatically glycated protein derivatives termed advanced glycation endproducts (AGE) are formed at an accelerated rate and accumulated in blood and in tissues. Studies performed in vitro and in vivo revealed AGE and their receptor RAGE as the major accounts for vascular cell derangement characteristic of diabetes. The AGERAGE system would thus be considered as a candidate molecular target for overcoming diabetic vascular complications. Potential preventive and therapeutic approaches toward it include inhibition of AGE formation, breakage of preformed AGE-proteins crosslinks, blockade of AGE-RAGE interactions with RAGE competitors or antagonists and RAGEspecific signaling inhibition.
Keywords: diabetic complications, advanced glycation endproducts (age), receptor for age (rage)
Current Drug Targets
Title: Blockade of Diabetic Vascular Injury by Controlling of AGE-RAGE System
Volume: 6 Issue: 4
Author(s): Khin Mar Myint, Yasuhiko Yamamoto, Shigeru Sakurai, Ai Harashima, Takuo Watanabe, Hui Li, Akihiko Takeuchi, Kazunobu Yoshimura, Hideto Yonekura and Hiroshi Yamamoto
Affiliation:
Keywords: diabetic complications, advanced glycation endproducts (age), receptor for age (rage)
Abstract: Vascular complications result in disabilities and short life expectancy in diabetic patients. During prolonged hyperglycemic exposure, non-enzymatically glycated protein derivatives termed advanced glycation endproducts (AGE) are formed at an accelerated rate and accumulated in blood and in tissues. Studies performed in vitro and in vivo revealed AGE and their receptor RAGE as the major accounts for vascular cell derangement characteristic of diabetes. The AGERAGE system would thus be considered as a candidate molecular target for overcoming diabetic vascular complications. Potential preventive and therapeutic approaches toward it include inhibition of AGE formation, breakage of preformed AGE-proteins crosslinks, blockade of AGE-RAGE interactions with RAGE competitors or antagonists and RAGEspecific signaling inhibition.
Export Options
About this article
Cite this article as:
Myint Mar Khin, Yamamoto Yasuhiko, Sakurai Shigeru, Harashima Ai, Watanabe Takuo, Li Hui, Takeuchi Akihiko, Yoshimura Kazunobu, Yonekura Hideto and Yamamoto Hiroshi, Blockade of Diabetic Vascular Injury by Controlling of AGE-RAGE System, Current Drug Targets 2005; 6 (4) . https://dx.doi.org/10.2174/1389450054021882
DOI https://dx.doi.org/10.2174/1389450054021882 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Etiology of Hypertension in the Metabolic Syndrome Part Four: The Systemic Perspective – The Role of the Neuroendocrine and Immune Systems,and the Challenge of Integration
Current Vascular Pharmacology Therapeutic Apheresis in Metabolic Syndrome
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Advanced Glycation End Products: A Link Between Periodontitis and Diabetes Mellitus?
Current Diabetes Reviews From the Table to the Bedside: Can Food-Derived Sulforaphane be used as a Novel Agent to Treat Leukemia?
Current Cancer Drug Targets The Management of the Infected Diabetic Foot
Current Diabetes Reviews Oral Glucose-lowering Drugs and Cardiovascular Outcomes: From the Negative RECORD and ACCORD to Neutral TECOS and Promising EMPA-REG
Current Vascular Pharmacology Insights into the Regulation of Renal Hemodynamic Function in Diabetic Mellitus
Current Diabetes Reviews A Comparative Literature Review Exploring Hypertension Drugs that Lower Target Organ Damage Above and Beyond Reducing Blood Pressure Based on Research Studies Between 1992 and 2006
Current Hypertension Reviews Vitamin D Therapy in Cardiac Hypertrophy and Heart Failure
Current Pharmaceutical Design Hydroximic Acid Derivatives: Pleiotropic Hsp Co-Inducers Restoring Homeostasis and Robustness
Current Pharmaceutical Design Review of Medicinal Plants and their Compounds for Aldose Reductase Inhibitory Activity
Letters in Drug Design & Discovery 12-Lipoxygenase: A Potential Target for Novel Anti-Platelet Therapeutics
Cardiovascular & Hematological Agents in Medicinal Chemistry Endothelial Dysfunction in Renal Failure: Current Update
Current Medicinal Chemistry Identifying Risk Factors for Clinically Significant Diabetic Macula Edema in Patients with Type 2 Diabetes Mellitus
Current Diabetes Reviews Renoprotective Effects of the L-/T-type Calcium Channel Blocker Benidipine in Patients with Hypertension
Current Hypertension Reviews Emerging Roles for Vasoactive Peptides in Diagnostic and Therapeutic Strategies Against Atherosclerotic Cardiovascular Diseases
Current Protein & Peptide Science Diabetes Mellitus and Renal Function: Current Medical Research and Opinion
Current Diabetes Reviews Increased Risk of Falls, Fall-related Injuries and Fractures in People with Type 1 and Type 2 Diabetes - A Nationwide Cohort Study
Current Drug Safety Taurine-Diabetes Interaction: From Involvement to Protection
Current Diabetes Reviews Dipeptide Inhibitors of Thermolysin and Angiotensin I-Converting Enzyme
Current Topics in Medicinal Chemistry